4/9
08:09 am
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
High
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
4/9
07:39 am
trvi
Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference [Yahoo! Finance]
Medium
Report
Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference [Yahoo! Finance]
4/9
07:30 am
trvi
Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference
Medium
Report
Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference
4/4
07:49 am
trvi
Trevi Therapeutics to Participate in Upcoming April Events [Yahoo! Finance]
Medium
Report
Trevi Therapeutics to Participate in Upcoming April Events [Yahoo! Finance]
4/4
07:30 am
trvi
Trevi Therapeutics to Participate in Upcoming April Events
Medium
Report
Trevi Therapeutics to Participate in Upcoming April Events
4/3
05:48 pm
trvi
Cough in Idiopathic Pulmonary Fibrosis Therapeutics Market to Exhibit Immense Growth at a CAGR of 4.9% by 2034 | DelveInsight [Yahoo! Finance]
Low
Report
Cough in Idiopathic Pulmonary Fibrosis Therapeutics Market to Exhibit Immense Growth at a CAGR of 4.9% by 2034 | DelveInsight [Yahoo! Finance]
4/2
07:39 am
trvi
Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team [Yahoo! Finance]
Low
Report
Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team [Yahoo! Finance]
4/2
07:30 am
trvi
Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team
Low
Report
Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team
3/21
09:37 am
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $9.00 price target on the stock.
High
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $9.00 price target on the stock.
3/21
08:06 am
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
Medium
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
3/20
04:16 pm
trvi
Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates [Yahoo! Finance]
High
Report
Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates [Yahoo! Finance]
3/20
04:05 pm
trvi
Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates
Medium
Report
Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates
3/13
04:05 pm
trvi
Trevi Therapeutics to Report Q4 and Year End 2023 Financial Results and Provide a Corporate Update on March 20, 2024
Medium
Report
Trevi Therapeutics to Report Q4 and Year End 2023 Financial Results and Provide a Corporate Update on March 20, 2024
2/29
05:53 am
trvi
private equity firms who own 35% along with institutions invested in Trevi Therapeutics, Inc. (NASDAQ:TRVI) saw increase in their holdings value last week [Yahoo! Finance]
Low
Report
private equity firms who own 35% along with institutions invested in Trevi Therapeutics, Inc. (NASDAQ:TRVI) saw increase in their holdings value last week [Yahoo! Finance]
2/28
07:30 am
trvi
Trevi Therapeutics to Participate in Upcoming March Events
Low
Report
Trevi Therapeutics to Participate in Upcoming March Events
2/6
07:34 am
trvi
Trevi Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
Medium
Report
Trevi Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
2/6
07:30 am
trvi
Trevi Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Medium
Report
Trevi Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
1/25
07:41 am
trvi
Global Idiopathic Pulmonary Fibrosis (IPF) Market Report 2024-2034: IPF Industry to Observe Robust Expansion with Emerging Therapies and Increasing Prevalence of Cough-Related IPF [Yahoo! Finance]
Low
Report
Global Idiopathic Pulmonary Fibrosis (IPF) Market Report 2024-2034: IPF Industry to Observe Robust Expansion with Emerging Therapies and Increasing Prevalence of Cough-Related IPF [Yahoo! Finance]